Elena Vagia

719 total citations · 1 hit paper
25 papers, 493 citations indexed

About

Elena Vagia is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Elena Vagia has authored 25 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Elena Vagia's work include Cancer Genomics and Diagnostics (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Research Studies (4 papers). Elena Vagia is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Research Studies (4 papers). Elena Vagia collaborates with scholars based in United States, Greece and Germany. Elena Vagia's co-authors include Massimo Cristofanilli, Devalingam Mahalingam, Amanda Psyrri, Panagiota Economopoulou, Ioannis Kotsantis, Μaria Anastasiou, Young Kwang Chae, Μαρία Γκοτζαμανίδου, Evangelos Giotakis and George Dimitriadis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Elena Vagia

21 papers receiving 490 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Landscape of Targeted Therapies in TNBC

2020 305 citations Elena Vagia, Devalingam Mahalingam et al. Cancers profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elena Vagia United States	9	256	226	153	125	82	25	493
Qifeng Ding China	10	169 0.7×	130 0.6×	86 0.6×	149 1.2×	57 0.7×	22	386
Manu Prasad Israel	12	146 0.6×	183 0.8×	83 0.5×	59 0.5×	54 0.7×	27	359
Lais Osmani United States	5	238 0.9×	305 1.3×	192 1.3×	261 2.1×	69 0.8×	10	613
Luís Palomero Spain	11	182 0.7×	274 1.2×	95 0.6×	73 0.6×	119 1.5×	14	492
Shoujie Chai China	10	204 0.8×	239 1.1×	143 0.9×	109 0.9×	42 0.5×	12	431
Margo P. Cain United States	6	199 0.8×	389 1.7×	236 1.5×	154 1.2×	98 1.2×	6	692
Silei Sui China	11	192 0.8×	248 1.1×	131 0.9×	134 1.1×	110 1.3×	13	474
Yu‐zhong Duan China	12	320 1.3×	306 1.4×	201 1.3×	107 0.9×	263 3.2×	26	713
Shi-Rong Zhang China	9	227 0.9×	221 1.0×	150 1.0×	78 0.6×	71 0.9×	11	441
Hui Guan China	8	180 0.7×	112 0.5×	72 0.5×	94 0.8×	125 1.5×	26	426

Countries citing papers authored by Elena Vagia

Since Specialization

Citations

This map shows the geographic impact of Elena Vagia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Vagia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Vagia more than expected).

Fields of papers citing papers by Elena Vagia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Vagia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Vagia. The network helps show where Elena Vagia may publish in the future.

Co-authorship network of co-authors of Elena Vagia

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Vagia. A scholar is included among the top collaborators of Elena Vagia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Vagia. Elena Vagia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gavrielatou, Niki, Aris Spathis, Μaria Anastasiou, et al.. (2023). B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma. Annals of Oncology. 35(4). 340–350. 29 indexed citations

Nicolò, Eleonora, Elena Vagia, Paolo D’Amico, et al.. (2023). Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of FGFR2-KIAA1598 Gene Fusion. JCO Precision Oncology. 7(7). e2200702–e2200702. 2 indexed citations

Kim, Min Jeong, et al.. (2022). Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review. The Oncologist. 27(7). 525–531. 7 indexed citations

Vagia, Elena & Massimo Cristofanilli. (2021). New Treatment Strategies for the Inflammatory Breast Cancer. Current Treatment Options in Oncology. 22(6). 50–50. 10 indexed citations

Jacob, Saya, Andrew A. Davis, Paolo D’Amico, et al.. (2021). Abstract PS2-10: Circulating tumor DNA (ctDNA) as a diagnostic tool to identify putative germline BRCA mutations. Cancer Research. 81(4_Supplement). PS2–10. 1 indexed citations

Park, Jonghanne, Youjin Oh, Elena Vagia, et al.. (2021). Blood transfusions may adversely affect survival outcomes of patients with lung cancer: a systematic review and meta-analysis. Translational Lung Cancer Research. 10(4). 1700–1710. 6 indexed citations

D’Amico, Paolo, Carolina Reduzzi, Sara Gandini, et al.. (2021). Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stageIV_aggressive breast cancer.. Journal of Clinical Oncology. 39(15_suppl). 3036–3036. 5 indexed citations

Mahalingam, Devalingam, Siqi Chen, Ping Xie, et al.. (2021). Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma.. Journal of Clinical Oncology. 39(15_suppl). 4144–4144. 3 indexed citations

Choi, Yoon‐Hee, et al.. (2021). Abstract 519: Hyperprogression in follicular thyroid cancer treated with combination immunotherapy. Cancer Research. 81(13_Supplement). 519–519.

10.

Choi, Yoon‐Hee, et al.. (2021). Metastatic CDK12-Mutated Neuroendocrine Tumor of Lung Showed an Exceptional Response to Olaparib and Paclitaxel. JCO Precision Oncology. 5(5). 751–755.

11.

Economopoulou, Panagiota, Μaria Anastasiou, George Papaxoinis, et al.. (2021). Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC). Cancers. 13(2). 286–286. 19 indexed citations

12.

Vagia, Elena, et al.. (2020). Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC). Cancer Immunology Immunotherapy. 70(4). 961–965. 33 indexed citations

13.

Economopoulou, Panagiota, Αreti Strati, Evangelos Giotakis, et al.. (2020). Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma. ESMO Open. 5(3). e000646–e000646. 22 indexed citations

14.

Vagia, Elena, Andrew A. Davis, Lorenzo Gerratana, et al.. (2020). Abstract 1501: Exceptional response to anti HER-2 targeted therapy in patient with HER2/neu negative breast cancer with HER2/neu positive CTCs. Cancer Research. 80(16_Supplement). 1501–1501.

15.

Mahalingam, Devalingam, Aparna Kalyan, Sheetal Kircher, et al.. (2020). Pembrolizumab in combination with the oncolytic virus pelareorep in patients progressing on systemic chemotherapy for advanced pancreatic adenocarcinoma: A phase II study.. Journal of Clinical Oncology. 38(15_suppl). e16789–e16789. 1 indexed citations

16.

Economopoulou, Panagiota, George Koutsodontis, Αreti Strati, et al.. (2019). Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC). Oral Oncology. 94. 93–100. 13 indexed citations

17.

Psyrri, Amanda, Niki Gavrielatou, Aris Spathis, et al.. (2019). Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142).. Journal of Clinical Oncology. 37(15_suppl). 6060–6060. 2 indexed citations

18.

Fostira, Florentia, George Koutsodontis, Elena Vagia, et al.. (2018). Predisposing Germline Mutations in Young Patients With Squamous Cell Cancer of the Oral Cavity. JCO Precision Oncology. 2(2). 1–8. 14 indexed citations

19.

Koutsodontis, George, Αreti Strati, Margaritis Avgeris, et al.. (2015). PDL1-expressing circulating tumor cells (CTCs) in head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 33(15_suppl). 6018–6018. 3 indexed citations

20.

Vagia, Elena, et al.. (2015). Androgen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone Treatment. Frontiers in Oncology. 5. 10–10. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact